# Abeona Therapeutics (ABEO) — News ABEO · NASDAQ · Stock Canonical page: https://www.lighthorse.io/tickers/abeo/news ## Recent headlines - [Cannabis stocks rose in premarket trading, with Green Thumb Industries up 16%, IGC Biosciences gaining 3.93% and Canopy Growth rising 2.77%.](https://www.ainvest.com/news/cannabis-stocks-rose-premarket-trading-green-thumb-industries-16-igc-biosciences-gaining-3-93-canopy-growth-rising-2-77-2610-1) — AInvest Wire, Oct 12, 2026 Cannabis stocks experienced gains in premarket trading on October 12, 2026, with Green Thumb Industries (GTBIF) rising 16% following a series of recent developments, including the expansion of its retail footprint in Florida and Nevada. The company recently opened its 25th Florida location, RISE… - [Abeona Therapeutics, Inc.: Oppenheimer cuts target price to $21 from $22](https://www.ainvest.com/news/abeona-therapeutics-oppenheimer-cuts-target-price-21-22-2608) — AInvest Wire, Aug 14, 2026 Oppenheimer & Co. has revised its price target for Abeona Therapeutics, Inc. (NASDAQ:ABEO) to $21 from $22, while maintaining its Outperform rating for the stock. The adjustment follows the firm’s updated analysis of the company’s recent developments, including progress in commercial launch of… - [Abeona Therapeutics 2Q loss/share 0.35c](https://www.ainvest.com/news/abeona-therapeutics-2q-loss-share-0-35c-2608) — AInvest Wire, Aug 13, 2026 Abeona Therapeutics Inc. (Nasdaq: ABEO) reported a net loss of $0.35 per share for the second quarter of 2026, reflecting continued financial challenges as the company transitions from a clinical-stage to a commercial-stage biopharmaceutical entity. The loss, while narrower than previous periods,… - [Abeona Therapeutics still targets 2027 for ABO-701 IND submission](https://www.ainvest.com/news/abeona-therapeutics-targets-2027-abo-701-ind-submission-2606) — AInvest Wire, Jun 4, 2026 Abeona Therapeutics Inc. (Nasdaq: ABEO) continues to target the second half of 2027 for the submission of an Investigational New Drug (IND) application for its lead development candidate, ABO-701, a novel engineered T-cell therapy targeting Prostate-Specific Membrane Antigen (PSMA) in advanced… - [Abeona Therapeutics: FDA pre-IND meeting for ABO-701 was constructive](https://www.ainvest.com/news/abeona-therapeutics-fda-pre-ind-meeting-abo-701-constructive-2606) — AInvest Wire, Jun 4, 2026 Abeona Therapeutics Inc. (Nasdaq: ABEO) has reported progress in its development pipeline for ABO-701, a novel engineered T-cell therapy targeting Prostate-Specific Membrane Antigen (PSMA) in advanced prostate cancer. The company recently held a pre-Investigational New Drug (IND) meeting with the… --- Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express. This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness. Data provided by [AInvest](https://www.ainvest.com).